| Primary |
| Product Used For Unknown Indication |
40.2% |
| Pain |
10.1% |
| Prophylaxis |
9.0% |
| Abscess |
6.0% |
| Anaesthesia |
5.0% |
| Breast Operation |
5.0% |
| Analgesic Therapy |
2.5% |
| Anesthesia |
2.5% |
| Urinary Tract Infection |
2.5% |
| Depression |
2.0% |
| Pyrexia |
2.0% |
| Thrombosis Prophylaxis |
2.0% |
| Antibiotic Prophylaxis |
1.5% |
| Cardiac Failure |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.5% |
| Hypertension |
1.5% |
| Odynophagia |
1.5% |
| Postoperative Analgesia |
1.5% |
| Biliary Colic |
1.0% |
| Chest Pain |
1.0% |
|
| Thrombocytopenia |
16.2% |
| Toxicity To Various Agents |
10.8% |
| Hepatocellular Injury |
8.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.4% |
| Hepatitis |
5.4% |
| Normochromic Normocytic Anaemia |
5.4% |
| Toxic Skin Eruption |
5.4% |
| Transaminases Increased |
5.4% |
| Vision Blurred |
5.4% |
| Vomiting |
5.4% |
| Acute Generalised Exanthematous Pustulosis |
2.7% |
| Acute Respiratory Distress Syndrome |
2.7% |
| Bone Marrow Failure |
2.7% |
| Cardio-respiratory Arrest |
2.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.7% |
| Eosinophilic Pneumonia |
2.7% |
| Gastrointestinal Haemorrhage |
2.7% |
| Hepatic Failure |
2.7% |
| Hepatitis Acute |
2.7% |
| Hepatitis Viral |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
35.3% |
| Drug Use For Unknown Indication |
20.2% |
| Anaesthesia |
7.5% |
| Pain |
5.0% |
| Prophylaxis |
4.3% |
| Maternal Exposure Timing Unspecified |
3.6% |
| Hypertension |
3.2% |
| Drug Exposure During Pregnancy |
2.4% |
| General Anaesthesia |
2.4% |
| Surgery |
2.0% |
| Thrombosis Prophylaxis |
1.9% |
| Foetal Exposure During Pregnancy |
1.8% |
| Postoperative Analgesia |
1.6% |
| Infection |
1.4% |
| Antibiotic Prophylaxis |
1.4% |
| Pancreatitis |
1.3% |
| Drug Exposure Via Mother |
1.2% |
| Induction Of Anaesthesia |
1.2% |
| Back Pain |
1.1% |
| Migraine |
1.1% |
|
| Thrombocytopenia |
10.9% |
| Stevens-johnson Syndrome |
10.0% |
| Toxic Epidermal Necrolysis |
10.0% |
| Renal Failure Acute |
9.5% |
| Cytolytic Hepatitis |
5.9% |
| Premature Baby |
5.5% |
| Neutropenia |
5.0% |
| Rash |
5.0% |
| Somnolence |
4.1% |
| Acute Generalised Exanthematous Pustulosis |
3.6% |
| Toxic Skin Eruption |
3.6% |
| Transaminases Increased |
3.6% |
| Cholestasis |
3.2% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.2% |
| Tachycardia |
3.2% |
| Foetal Growth Restriction |
2.7% |
| Hepatocellular Injury |
2.7% |
| Respiratory Failure |
2.7% |
| Urticaria |
2.7% |
| Vomiting |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
23.5% |
| Product Used For Unknown Indication |
17.3% |
| Pain |
12.4% |
| Prophylaxis |
8.6% |
| Hypertension |
6.1% |
| Premedication |
4.0% |
| Thrombosis Prophylaxis |
3.9% |
| Nausea |
3.0% |
| Anaesthesia |
2.7% |
| Pyrexia |
2.5% |
| Diabetes Mellitus |
2.1% |
| Sarcoma |
2.0% |
| Infection Prophylaxis |
1.9% |
| Acute Myeloid Leukaemia |
1.8% |
| Psoas Abscess |
1.7% |
| General Anaesthesia |
1.4% |
| Pneumonia |
1.4% |
| Constipation |
1.3% |
| Sleep Disorder |
1.2% |
| Hodgkin's Disease |
1.2% |
|
| Thrombocytopenia |
14.1% |
| Renal Failure Acute |
12.2% |
| Vomiting |
6.8% |
| Sepsis |
6.4% |
| Renal Failure |
5.5% |
| Stevens-johnson Syndrome |
5.1% |
| Tachycardia |
5.1% |
| Pancreatitis Acute |
4.8% |
| Death |
4.2% |
| Weight Decreased |
4.2% |
| Septic Shock |
3.9% |
| Rash |
3.5% |
| Urticaria |
3.5% |
| Neutropenia |
3.2% |
| Toxic Epidermal Necrolysis |
3.2% |
| Toxic Skin Eruption |
3.2% |
| Tremor |
2.9% |
| Urinary Tract Infection |
2.9% |
| Acute Respiratory Failure |
2.6% |
| Pancytopenia |
2.6% |
|
| Interacting |
| Anaesthesia |
75.0% |
| Premedication |
25.0% |
|
|
